– Bloomberg
Helbiz Skyrockets After After Investigation Into Short Selling
Helbiz Inc (NASDAQ:HLBZ) said its Board has begun examining measures to address the alleged illegal short selling of its stock. The…
Related Posts
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $102
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $100 to $102.
Citigroup Initiates Coverage On Kinetik Holdings with Buy Rating, Announces Price Target of $36
Citigroup analyst Spiro Dounis initiates coverage on Kinetik Holdings (NYSE:KNTK) with a Buy rating and announces Price Target of $36.
Lululemon’s Strategic Plan Pays Off As Data Reveals Evolving Demographics
Lululemon Athletica Inc (NASDAQ: LULU) reported a 30% sales increase last year, outperforming its initial projections.